1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

Array paying next to nothing for Novartis BRAF inhibitor

 
• By Mandy Jackson

As its acquisition of GlaxoSmithKline's oncology portfolio draws nearer to closing, Novartis is essentially paying Array BioPharma to take over development and commercialization of the BRAF inhibitor encorafenib (LGX818) just one month after the Swiss big pharma gave back its rights to Array's MEK inhibitor binimetinib under attractive terms.

As its acquisition of GlaxoSmithKline's oncology portfolio draws nearer to closing, Novartis is essentially paying Array BioPharma to take over development and commercialization of the BRAF inhibitor encorafenib (LGX818) just one month after the Swiss big pharma gave back its rights to Array's MEK inhibitor binimetinib under attractive terms.

Array closed up 40.8% at $7.11 per share on 23 January after the Boulder, Colorado-based company announced the encorafenib agreement,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

Immuneering Could Partner Atebimetinib Or Go It Alone After Phase IIa Success

 
• By Alaric DeArment

CEO Ben Zeskind said all options are on the table after atebimetinib showed impressive results in pancreatic cancer.

Enliven Raises $230m To Fund Scemblix Leukemia Challenger

 
• By Andrew McConaghie

The company believes its drug could eventually displace Novartis’s Scemblix in first-line chronic myeloid leukemia treatment, but for now is preparing for a second-/third-line pivotal study.

BMS’s Breyanzi Stands To Further Expand Broad Lymphoma Coverage

 
• By Alaric DeArment

The drugmaker presented data at a lymphoma meeting showing strong efficacy for the CAR-T in marginal zone lymphoma, the second most common indolent lymphoma.

Early Blood Cancer Data Impresses As Incyte Plots Post-Jakafi Strategy

 
• By Kevin Grogan

First results for a first-in-class mutCALR-targeted therapy in essential thrombocythemia presented at EHA point to a lucrative future for the early-stage product.

More from Therapy Areas

Enliven Raises $230m To Fund Scemblix Leukemia Challenger

 
• By Andrew McConaghie

The company believes its drug could eventually displace Novartis’s Scemblix in first-line chronic myeloid leukemia treatment, but for now is preparing for a second-/third-line pivotal study.

Sarepta Market Dynamics For Elevidys Imperiled By Second Patient Death

 
• By Joseph Haas

With two deaths in non-ambulatory DMD patients, Sarepta is attempting damage control and will ask the US FDA to advise, setting up a possible confrontation with CBER director Prasad.

Supernus Secures Sage With CVR-Supported Deal

 
• By Jessica Merrill

Supernus agreed to pay $561m upfront plus a contingent value right that could add $234m to buy Sage, topping a previously rejected offer from Biogen.